A Critical Review of the Effects of Hydroxychloroquine and Chloroquine on the Eye

Clinical Reviews in Allergy and Immunology

Volumn 49, Issue 3, 2015, Pages 317-326

  Costedoat Chalumeau, Nathalie ^a,b   Dunogué, Bertrand ^a,b   Leroux, Gaëlle ^c   Morel, Nathalie ^a,b   Jallouli, Moez ^a,b   Le Guern, Véronique ^a,b   Piette, Jean Charles ^c   Brézin, Antoine P ^a,b   Melles, Ronald B ^d   Marmor, Michael F ^e  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b AP HP ^*  (France)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d KAISER PERMANENTE MEDICAL CENTER   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antimalarials; Chloroquine; Drug toxicity; Hydroxychloroquine; Retinopathy; Systemic lupus erythematosus

Indexed keywords

ANTIMALARIAL AGENT; CHLOROQUINE; HYDROXYCHLOROQUINE; PLACEBO; TAMOXIFEN;

ACCOMMODATION DISORDER; AGE; CATARACT; CENTRAL SCOTOMA; DISEASE PREDISPOSITION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG WITHDRAWAL; ELECTRORETINOGRAPHY; EYE TOXICITY; GASTROINTESTINAL TOXICITY; GLOMERULUS FILTRATION RATE; HUMAN; INCIDENCE; KERATOPATHY; KIDNEY DISEASE; LONG TERM EXPOSURE; MULTICENTER STUDY (TOPIC); NONHUMAN; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; PATIENT SAFETY; PIGMENT DISORDER; PRENATAL DRUG EXPOSURE; PRESCRIPTION; PROGENY; RACE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA INJURY; RETINA MACULOPATHY; RETINITIS PIGMENTOSA; RETINOPATHY; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SKIN LUPUS ERYTHEMATOSUS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; VISUAL FIELD DEFECT; ANIMAL; COMPLICATION; DOSE CALCULATION; DRUG EFFECTS; EYE DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; PATHOLOGY; RETINA;

ANIMALS; CHLOROQUINE; DRUG DOSAGE CALCULATIONS; EYE DISEASES; HUMANS; HYDROXYCHLOROQUINE; LUPUS ERYTHEMATOSUS, SYSTEMIC; RETINA;

EID: 84947612144     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-015-8469-8     Document Type: Review

References (69)

1. Costedoat-Chalumeau N, Leroux G, Piette J-C, Amoura Z (2010) Antimalarials and systemic lupus erythematosus. In: Lahita RG, Tsokos G, Buyon JP, Koike T (eds) Systemic lupus erythematosus, 5th edn. Elsevier, 1061–1081
2. Ruiz-Irastorza G, Egurbide MV, Pijoan JI et al (2006) Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 15:577–583
3. Alarcon GS, McGwin G Jr, Bertoli AM et al (2007) Effect of hydroxychloroquine in the survival of patients with systemic lupus erythematosus. data from lumina, a multiethnic us cohort (LUMINA L). Ann Rheum Dis 66:1168–1172
4. Shinjo SK, Bonfa E, Wojdyla D et al (2010) Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum 62:855–862
5. Costedoat-Chalumeau N, Hulot JS, Amoura Z et al (2006) Cardiomyopathy related to antimalarial therapy with illustrative case report. Cardiology 107:73–80
6. Melles RB, Marmor MF (2014) The risk of toxic retinopathy in long-term hydroxychloroquine therapy. JAMA Ophthalmol 132:1453–1460
7. Marmor MF, Kellner U, Lai TY, Lyons JS, Mieler WF (2011) Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology 118:415–422
8. Marmor MF, Hu J (2014) Effect of disease stage on progression of hydroxychloroquine retinopathy. JAMA Ophthalmol 132:1105–1112
9. Yam JC, Kwok AK (2006) Ocular toxicity of hydroxychloroquine. Hong Kong Med J 12:294–304
10. Grierson DJ (1997) Hydroxychloroquine and visual screening in a rheumatology outpatient clinic. Ann Rheum Dis 56:188–190
11. Dosso A, Rungger-Brandle E (2007) In vivo confocal microscopy in hydroxychloroquine-induced keratopathy. Graefes Arch Clin Exp Ophthalmol 245:318–320
12. Tehrani R, Ostrowski RA, Hariman R, Jay WM (2008) Ocular toxicity of hydroxychloroquine. Semin Ophthalmol 23:201–209
13. Marmor MF (2012) Comparison of screening procedures in hydroxychloroquine toxicity. Arch Ophthalmol 130:461–469
14. Melles RB, Marmor MF (2015) Pericentral retinopathy and racial differences in hydroxychloroquine toxicity. Ophthalmology 122:110-116
15. Lee DH, Joe SG, Lee JY, Kim J-G, Lee CG, Yoo B, Koo BS, Melles RB, Marmor, MF, Yoon, YH (2015) Pericentral hydroxychloroquine retinopathy in Korean patients. Ophthalmology (in press)
16. Wolfe F, Marmor MF (2010) Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken) 62:775–784
17. Mackenzie AH (1983) Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am J Med 75:40–45
18. Bergholz R, Schroeter J, Ruther K (2010) Evaluation of risk factors for retinal damage due to chloroquine and hydroxychloroquine. Br J Ophthalmol 94:1637–1642
19. Easterbrook M (2002) Screening for antimalarial toxicity: current concepts. Can J Ophthalmol 37:325–328
20. Mititelu M, Wong BJ, Brenner M, Bryar PJ, Jampol LM, Fawzi AA (2013) Progression of hydroxychloroquine toxic effects after drug therapy cessation: new evidence from multimodal imaging. JAMA Ophthalmol 131:1187–1197
21. Costedoat-Chalumeau N, Pouchot J, Guettrot-Imbert G et al (2013) Adherence to treatment in systemic lupus erythematosus patients. Best Pract Res Clin Rheumatol 27:329–340
22. Costedoat-Chalumeau N, Galicier L, Aumaitre O et al (2013) Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). Ann Rheum Dis 72:1786–1792
23. Tett SE, Cutler DJ, Day RO (1992) Bioavailability of hydroxychloroquine tablets assessed with deconvolution techniques. J Pharm Sci 81:155–159
24. Lee JY, Luc S, Greenblatt DJ, Kalish R, McAlindon TE (2013) Factors associated with blood hydroxychloroquine level in lupus patients: renal function could be important. Lupus 22:541–542
25. Shroyer NF, Lewis RA, Lupski JR (2001) Analysis of the ABCR (ABCA4) gene in 4-aminoquinoline retinopathy: is retinal toxicity by chloroquine and hydroxychloroquine related to Stargardt disease? Am J Ophthalmol 131:761–766
26. Munster T, Gibbs JP, Shen D et al (2002) Hydroxychloroquine concentration-response relationships in patients with rheumatoid arthritis. Arthritis Rheum 46:1460–1469
27. Tett SE, Cutler DJ, Beck C, Day RO (2000) Concentration-effect relationship of hydroxychloroquine in patients with rheumatoid arthritis—a prospective, dose ranging study. J Rheumatol 27:1656–1660
28. Tett SE, Day RO, Cutler DJ (1993) Concentration-effect relationship of hydroxychloroquine in rheumatoid arthritis—a cross sectional study. J Rheumatol 20:1874–1879
29. Frances C, Cosnes A, Duhaut P et al (2012) Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study. Arch Dermatol 148:479–484
30. Costedoat-Chalumeau N, Amoura Z, Hulot JS et al (2006) Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus. Arthritis Rheum 54:3284–3290
31. Carmichael SJ, Day RO, Tett SE (2013) A cross-sectional study of hydroxychloroquine concentrations and effects in people with systemic lupus erythematosus. Intern Med J 43:547–553
32. Ting TV, Kudalkar D, Nelson S et al (2012) Usefulness of cellular text messaging for improving adherence among adolescents and young adults with systemic lupus erythematosus. J Rheumatol 39:174–179
33. Costedoat-Chalumeau N, Le Guern V, Piette JC (2014) Determining adherence to therapeutic regimens in patients with chronic illness: comment on the article by Waimann et Al. Arthritis Rheum 66:770
34. Alexander S, Chusney G, Chusney VD, Lee J, Cairns T, Lightstone L (2013) The Achilles heel of lupus nephritis treatment—identifying non adherence using hydroxychloroquine blood levels (abstract). J Am Soc Nephrol
35. Petri M, Fand H, Clarke W (2013) Hydroxychloroquine levels identify four distinct subsets of systemic lupus erythematosus patients (abstract). Arthritis Rheum 65:S770
36. Jallouli M, Frances C, Piette JC et al (2013) Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study. JAMA Dermatol 149:935–940
37. Carr RE, Henkind P, Rothfield N, Siegel IM (1968) Ocular toxicity of antimalarial drugs. Long-term follow-up. Am J Ophthalmol 66:738–744
38. Easterbrook M (1992) Long-term course of antimalarial maculopathy after cessation of treatment. Can J Ophthalmol 27:237–239
39. Easterbrook M (1993) The ocular safety of hydroxychloroquine. Semin Arthritis Rheum 23:62–67
40. Yam JC, Kwok AK (2014) Ultraviolet light and ocular diseases. Int Ophthalmol 34:383–400
41. Kijlstra A, Tian Y, Kelly ER, Berendschot TT (2012) Lutein: more than just a filter for blue light. Prog Retin Eye Res 31:303–315
42. Ozawa Y, Sasaki M, Takahashi N, Kamoshita M, Miyake S, Tsubota K (2012) Neuroprotective effects of lutein in the retina. Curr Pharm Des 18:51–56
43. Chew EY, Clemons TE, Sangiovanni JP et al (2014) Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmol 132:142–149
44. Marmor MF, Hu J (2014) Effect of disease stage on progression of hydroxychloroquine retinopathy. JAMA Ophthalmol 132(9):1105–1112
45. Marmor MF, Melles RB (2014) Disparity between visual fields and optical coherence tomography in hydroxychloroquine retinopathy. Ophthalmology 121:1257–1262
46. Missner S, Kellner U (2012) Comparison of different screening methods for chloroquine/hydroxychloroquine retinopathy: multifocal electroretinography, color vision, perimetry, ophthalmoscopy, and fluorescein angiography. Graefes Arch Clin Exp Ophthalmol 250:319–325
47. Rigaudiere F, Ingster-Moati I, Hache JC et al (2004) Up-dated ophthalmological screening and follow-up management for long-term antimalarial treatment. J Fr Ophtalmol 27:191–199
48. Kellner U, Renner AB, Tillack H (2006) Fundus autofluorescence and mfERG for early detection of retinal alterations in patients using chloroquine/hydroxychloroquine. Invest Ophthalmol Vis Sci 47:3531–3538
49. Lyons JS, Severns ML (2007) Detection of early hydroxychloroquine retinal toxicity enhanced by ring ratio analysis of multifocal electroretinography. Am J Ophthalmol 143:801–809
50. Anderson C, Blaha GR, Marx JL (2011) Humphrey visual field findings in hydroxychloroquine toxicity. Eye (Lond) 25:1535–1545
51. Semmer AE, Lee MS, Harrison AR, Olsen TW (2008) Hydroxychloroquine retinopathy screening. Br J Ophthalmol 92:1653–1655
52. Nika M, Blachley TS, Edwards P, Lee PP, Stein JD (2014) Regular examinations for toxic maculopathy in long-term chloroquine or hydroxychloroquine users. JAMA Ophthalmol 132(10):1199–1208
53. Costedoat-Chalumeau N, Amoura Z, Aymard G et al (2002) Evidence of transplacental passage of hydroxychloroquine in humans. Arthritis Rheum 46:1123–1124
54. Parke A, West B (1996) Hydroxychloroquine in pregnant patients with systemic lupus erythematosus. J Rheumatol 23:1715–1718
55. Buchanan NM, Toubi E, Khamashta MA, Lima F, Kerslake S, Hughes GR (1996) Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases. Ann Rheum Dis 55:486–488
56. Motta M, Tincani A, Faden D, Zinzini E, Chirico G (2002) Antimalarial agents in pregnancy. Lancet 359:524–525
57. Klinger G, Morad Y, Westall CA et al (2001) Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet 358:813–814
58. Levy RA, Vilela VS, Cataldo MJ et al (2001) Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 10:401–404
59. Clowse ME, Magder L, Witter F, Petri M (2006) Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 54:3640–3647
60. Costedoat-Chalumeau N, Amoura Z, Duhaut P et al (2003) Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. Arthritis Rheum 48:3207–3211
61. Sperber K, Hom C, Chao CP, Shapiro D, Ash J (2009) Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases. Pediatr Rheumatol Online J 7:9
62. Diav-Citrin O, Blyakhman S, Shechtman S, Ornoy A (2013) Pregnancy outcome following in utero exposure to hydroxychloroquine: a prospective comparative observational study. Reprod Toxicol 39C:58–62
63. Cimaz R, Brucato A, Meregalli E, Muscara M, Sergi P (2004) Electroretinograms of children born to mothers treated with hydroxychloroquine during pregnancy and breast-feeding: comment on the article by Costedoat-Chalumeau et al. Arthritis Rheum 50:3056–3057, author reply 3057–3058
64. Costedoat-Chalumeau N, Amoura Z, Sebbough D, Piette JC (2004) Reply. Arthritis Rheum 50:3057
65. Motta M, Tincani A, Faden D et al (2004) Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. J Perinatol 14:14
66. Renault F, Flores-Guevara R, Renaud C, Richard P, Vermersch AI, Gold F (2009) Visual neurophysiological dysfunction in infants exposed to hydroxychloroquine in utero. Acta Paediatr 98:1500–1503
67. Ingster-Moati I, Albuisson E (2010) Visual neurophysiological dysfunction in infants exposed to hydroxychloroquine in utero. Acta Paediatr 99:4, author reply 4–5
68. Osadchy A, Ratnapalan T, Koren G (2011) Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature. J Rheumatol 38:2504–2508
69. Ostensen M, Khamashta M, Lockshin M et al (2006) Anti-inflammatory and immunosuppressive drugs and reproduction. Arthritis Res Ther 8:209